• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Reducing dose of popular blood thinners may limit risk of future bleeding, study finds

December 19, 2024
in Medical Research
Reading Time: 3 mins read
A A
0
prescription
6
SHARES
13
VIEWS
Share on FacebookShare on Twitter


prescription
Credit: Pixabay/CC0 Public Domain

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.

The research team focused the study on the two most prescribed direct oral anticoagulants, or DOACs, rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis).

Investigators analyzed nearly 1,000 cases of patients who were treated for a blood clot, also known as venous thromboembolism, and who were taking the medications to prevent one from recurring.

Some patients had their doses reduced after six months, while others stayed on the full therapeutic dose.

While both treatments resulted in a similar rate of recurrent clotting, the therapeutic dosing of either DOAC was associated with an increased risk of bleeding, emergency department visits and hospitalizations compared a reduced dose.

The results were presented as an abstract at the 2024 American Society of Hematology Annual Meeting & Exposition.

“These popular DOACs can be lifesaving treatments, but they come with an increased risk of bleeding and must be carefully monitored when prescribed to patients,” said lead author Jordan K. Schaefer, M.D., M.Sc., clinical associate professor of internal medicine-hematology at University of Michigan Medical School.

“While previous studies have shown that rates of recurrent venous thromboembolism did not change when the DOAC dose was reduced after six months, our results suggest a higher risk of bleeding events and health care utilization for patients continuing therapeutic dosing. This raises a question if dose reduction could be beneficial for some patients.”

In 2021, the American College of Chest Physicians released clinical guidelines that suggested reduced dosage of either apixaban or rivaroxaban for extended management of blood clots, noting this was a “weak recommendation” with “very low certainty evidence.”

The findings support the 2021 guidelines.

The research team notes, however, that they need to be confirmed with randomized trials.

“In the absence of randomized trial data, these results provide the best supporting evidence that we can safely reduce the dose of DOACs in many patients to prevent recurrent VTE and avoid bleeding complications,” said Geoffrey Barnes, M.D., M.Sc., senior author and associate professor of cardiology-internal medicine at U-M Medical School.

More information:
Jordan K Schaefer et al. Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management, ash.confex.com/ash/2024/webpro … ram/Paper197878.html

Provided by
University of Michigan


Citation:
Reducing dose of popular blood thinners may limit risk of future bleeding, study finds (2024, December 19)
retrieved 19 December 2024
from https://medicalxpress.com/news/2024-12-dose-popular-blood-thinners-limit.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



prescription
Credit: Pixabay/CC0 Public Domain

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.

The research team focused the study on the two most prescribed direct oral anticoagulants, or DOACs, rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis).

Investigators analyzed nearly 1,000 cases of patients who were treated for a blood clot, also known as venous thromboembolism, and who were taking the medications to prevent one from recurring.

Some patients had their doses reduced after six months, while others stayed on the full therapeutic dose.

While both treatments resulted in a similar rate of recurrent clotting, the therapeutic dosing of either DOAC was associated with an increased risk of bleeding, emergency department visits and hospitalizations compared a reduced dose.

The results were presented as an abstract at the 2024 American Society of Hematology Annual Meeting & Exposition.

“These popular DOACs can be lifesaving treatments, but they come with an increased risk of bleeding and must be carefully monitored when prescribed to patients,” said lead author Jordan K. Schaefer, M.D., M.Sc., clinical associate professor of internal medicine-hematology at University of Michigan Medical School.

“While previous studies have shown that rates of recurrent venous thromboembolism did not change when the DOAC dose was reduced after six months, our results suggest a higher risk of bleeding events and health care utilization for patients continuing therapeutic dosing. This raises a question if dose reduction could be beneficial for some patients.”

In 2021, the American College of Chest Physicians released clinical guidelines that suggested reduced dosage of either apixaban or rivaroxaban for extended management of blood clots, noting this was a “weak recommendation” with “very low certainty evidence.”

The findings support the 2021 guidelines.

The research team notes, however, that they need to be confirmed with randomized trials.

“In the absence of randomized trial data, these results provide the best supporting evidence that we can safely reduce the dose of DOACs in many patients to prevent recurrent VTE and avoid bleeding complications,” said Geoffrey Barnes, M.D., M.Sc., senior author and associate professor of cardiology-internal medicine at U-M Medical School.

More information:
Jordan K Schaefer et al. Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management, ash.confex.com/ash/2024/webpro … ram/Paper197878.html

Provided by
University of Michigan


Citation:
Reducing dose of popular blood thinners may limit risk of future bleeding, study finds (2024, December 19)
retrieved 19 December 2024
from https://medicalxpress.com/news/2024-12-dose-popular-blood-thinners-limit.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Former top aide to New York City’s mayor surrenders to DA’s office to face charges

Next Post

As Trump’s Return Looms, Biden Commits U.S. To More Stringent Emissions Target

Related Posts

Higher linoleic acid levels linked to lower heart disease and diabetes risk

Higher linoleic acid levels linked to lower heart disease and diabetes risk

June 1, 2025
4
CAR T cell therapy

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

June 1, 2025
4
Next Post
biden meeting

As Trump's Return Looms, Biden Commits U.S. To More Stringent Emissions Target

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Aid ship set sail from Sicily with aid for Gaza

Aid ship set sail from Sicily with aid for Gaza

June 1, 2025
Spike in steel tariffs could imperil Trump promise of lower grocery prices

Spike in steel tariffs could imperil Trump promise of lower grocery prices todayheadline

June 1, 2025
Lake Resources Q1 2025 slides: Kachi Project advances amid lithium market headwinds

Lake Resources Q1 2025 slides: Kachi Project advances amid lithium market headwinds todayheadline

June 1, 2025
Social Security payments could shrink for some recipients in June — here's why

Social Security payments could shrink for some recipients in June — here’s why todayheadline

June 1, 2025

Recent News

Aid ship set sail from Sicily with aid for Gaza

Aid ship set sail from Sicily with aid for Gaza

June 1, 2025
3
Spike in steel tariffs could imperil Trump promise of lower grocery prices

Spike in steel tariffs could imperil Trump promise of lower grocery prices todayheadline

June 1, 2025
8
Lake Resources Q1 2025 slides: Kachi Project advances amid lithium market headwinds

Lake Resources Q1 2025 slides: Kachi Project advances amid lithium market headwinds todayheadline

June 1, 2025
5
Social Security payments could shrink for some recipients in June — here's why

Social Security payments could shrink for some recipients in June — here’s why todayheadline

June 1, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Aid ship set sail from Sicily with aid for Gaza

Aid ship set sail from Sicily with aid for Gaza

June 1, 2025
Spike in steel tariffs could imperil Trump promise of lower grocery prices

Spike in steel tariffs could imperil Trump promise of lower grocery prices todayheadline

June 1, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co